PRDM9 and diffuse large B-cell lymphoma: Despite emerging evidence demonstrate that mutations associated with altered epigenomes are common in T-ALL, epigenetic modifying drugs are not traditionally used to treat this disease; whereas, inhibitors targeting histone methyltransferases and histone demethylases are currently being tested in clinical trials as therapies for diffuse large B cell lymphoma (DLBCL) and AML (Morera et al., 2016).